Skip to main content
Premium Trial:

Request an Annual Quote

Coda Genomics Closes $1.6M in Series B Funding

NEW YORK, Feb. 28 (GenomeWeb News) - Coda Genomics said today that it has secured $1.6 million in a Series B funding round.

 

The round was led by the Life Science Angels and includes venture capital firm Monitor Ventures and previous investors from the Tech Coast Angels. The round has two representatives on the Coda board of directors: Ken Kelley from the Life Science Angels, and Neal Bhadkamkar from Monitor Ventures.

 

Coda offers gene kits and services optimized to assemble DNA into single genes that the company said "are guaranteed to express specific proteins." The genes are optimized for correct self assembly, and also for characteristics that guarantee they express the desired protein at high levels in a biological expression system of choice, Coda said.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.